F53. DOSE REDUCTION OF HIGH-DOSE FIRST-GENERATION ANTIPSYCHOTICS OR SWITCH TO ZIPRASIDONE IN LONG-STAY PATIENTS WITH SCHIZOPHRENIA: A 1-YEAR DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL
Sign Up to like & getrecommendations! Published in 2018 at "Schizophrenia Bulletin"
DOI: 10.1093/schbul/sby017.584
Abstract: Abstract Background Long-stay patients with severe schizophrenia are frequently treated with high doses of first-generation antipsychotics (FGA). Dose reduction or switching to ziprasidone may reduce the severity of negative symptoms or side effects. Methods In… read more here.
Keywords: reduction; fga dose; long stay; stay patients ... See more keywords
Sustained Release Ziprasidone Microparticles Prepared by Spray Drying with Soluplus® and Ethyl Cellulose to Eliminate Food Effect and Enhance Bioavailability
Sign Up to like & getrecommendations! Published in 2019 at "AAPS PharmSciTech"
DOI: 10.1208/s12249-019-1592-8
Abstract: The purpose of this study was to develop and evaluate a new formulation of ziprasidone (ZIP) for improved fasted state absorption and sustained drug release. ZIP solid dispersions were produced via spray drying using Soluplus®,… read more here.
Keywords: zip; ziprasidone; spray drying; sustained release ... See more keywords
Ziprasidone Induces Rabbit Atrium Arrhythmogenesis via Modification of Oxidative Stress and Sodium/Calcium Homeostasis
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10050976
Abstract: Background: Atypical antipsychotics increase the risk of atrial arrhythmias and sudden cardiac death. This study investigated whether ziprasidone, a second-generation antipsychotic, affected intracellular Ca2+ and Na+ regulation and oxidative stress, providing proarrhythmogenic substrates in atriums.… read more here.
Keywords: ziprasidone; oxidative stress; ziprasidone treated; atrial myocytes ... See more keywords